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Abbreviations {#nc005}
=============

RMI

:   Rehman Medical Institute

FPIA

:   Fluorescence Polarization Immunoassay

CAD

:   Coronary artery disease

QCA

:   Quantification of coronary atherosclerosis

SVCAD

:   Single vessel coronary artery disease

DVCAD

:   Double vessel coronary artery disease

TVCAD

:   Triple vessel coronary artery disease

BMS

:   Bare metal stent

PCI

:   Percutaneous Cutaneous Intervention

Introduction {#s0005}
============

One third of global deaths are caused by cardiovascular events [@b0005]. In developed countries such as the United States, \>600,000 deaths annually are attributed to cardiovascular diseases [@b0010]. Ischmeic heart disease is the biggest culprit contributing to mortality from heart diseases [@b0015]. Atherosclerosis is the hallmark of ischemic heart disease which is characterized by narrowing or blockage of coronary arteries supplying all the nutrients and oxygen to the heart [@b0020]. Coronary angiography is the gold standard for detecting coronary artery disease [@b0025].

Homocysteine accelerates atherosclerosis by increasing the prothrombotic factors XII and V and decreasing the antithrombotic factors along with endothelial derived nitric oxide. Hyper-homocysteinemia also inculcates direct endothelial cell damage, which leads to smooth muscle cells hyperplasia, contributing to occlusion or narrowing of the vessels. Increased plasma levels of homocysteine contribute to cardiac morbidities and it has positive association with hypertension [@b0030]. Aspirin resistance is also increased with high levels of homocysteine in the blood [@b0035]. Therefore, homocysteine has been thought of as an independent risk factor contributing to coronary artery disease and the Framingham Risk score has been challenged [@b0040]. Low levels of vitamin B12 and high serum concentration of homocysteine have been associated with coronary artery disease in Asians and investigated by two different studies in the Indian population [@b0045], [@b0050]. Homocysteine is a modifiable risk factor and folic acid supplementation improves the endothelial dysfunction caused by high serum concentration of homocysteine [@b0055].

The vascular toxicity of hyper-homocystenemia is well established, yet we have limited evidence regarding the isolated effect of hyper-homocystenemia on coronary artery disease in the younger population in absence of cumulative and synergistic effect of conventional strong risk factors. This study aimed to analyze the correlation of serum homocysteine and coronary artery disease in young adults in the absence of conventional risk factors. As it is a modifiable risk factor, targeting it will decrease both the cardiovascular mortality and morbidity.

Materials and methods {#s0010}
=====================

This study was carried out at the Cardiology Department of Rehman Medical Institute (RMI), Peshawar, Pakistan. RMI is a specialized tertiary care hospital providing modern state of the art facilities to patients from across the province and neighboring countries. It was an observational case-control study carried out for a period of 12 months from October 1, 2016, to September 30, 2017. A total of 158 participants were included; 128 participants in the patient group and 30 participants in the control group.

In the patient group, a universal sampling technique was adopted and every patient who had angiographic evidence of moderate to severe stenosis in single or multiple major coronary arteries on coronary angiography aged \<40 years and \>25 years was included. In the control group, random sampling from the general population was done having features similar to the participants of the patient group. Patients from each sex, different ethnic backgrounds, multiple geographic locations, and different socioeconomic statuses were part of the study population in both groups.

All those participants who had mild stenosis in coronary arteries, were using antihypertensive medications including calcium channel blockers, beta blockers, diuretics, or had a blood pressure measurement of \>140 mmHg systolic and \>100 mmHg diastolic, were using antidiabetic medications including oral antidiabetics or insulin or had a random blood glucose level of \>200 mg/dL, fasting blood glucose level of \>126 mg/dL or HbA1c of \>6.5%, were active smokers and smoked more than one cigarette daily, had familial hyperlipidemia or dyslipidemia, or had blood cholesterol level \>250 mg/dL, taking drugs such as antidepressants (S-adenosyl methionine), methotrexate, phenytoin, carbamazepine, 6-azauridine triacetate, recently undergone general anesthesia or were exposed to nitrous oxide were excluded from the study population.

In an EDTA tube, 5 mL fasting blood sample was collected under aseptic technique, having 8 hours fasting cutoff index. Plasma homocysteine level was assessed, using Fluorescence Polarization Immunoassay (FPIA) technique on AxSYM System (Abbott Laboratories Lake Bluff, Illinois, United States), by standard method. Highly selective conversion of homocysteine to S-adenosylhomocysteine by the enzyme S-adenosylhomocysteine hydrolase was the basic principle of this technique. FPIA is the accepted method of homocysteine analysis worldwide [@b0060], [@b0065].

This study was approved by the research and evaluation unit of Rehman Medical Institute after scrutiny of synopsis by research evaluation committee vide letter reference No: RMC/NOC/16 dated September 20, 2015, and abided by the declaration of Helsinki. Informed written consent obtained and confidentiality of the patient was ensured.

The Shapiro-Wilk test was applied to check the distribution of data. Continuous variables determined as mean ± standard deviation test and categorical variables expressed as frequencies and percentages. Analysis of variance (ANOVA) was used for comparison of the mean. Pearson test was used to compare the severity of hyper-homocysteinemia with severity of coronary artery disease and number of coronary artery disease. A *p* value \<0.5 was considered significant.

Operational definitions {#s0015}
-----------------------

Coronary artery disease (CAD) was defined as stenosis on coronary angiography using the quantification of coronary atherosclerosis (QCA) scoring system. Mild CAD was defined as \<30% stenosis in coronary arteries. Moderate CAD was defined as 30--70% stenosis in coronary arteries. Severe CAD was defined as \>70% stenosis in coronary arteries.

Patients having moderate to severe stenosis in single vessels were labelled as single vessel coronary artery disease (SVCAD). Patients having moderate to severe stenosis in two major vessels were labelled as double vessel coronary artery disease (DVCAD). Patients having moderate to severe stenosis in three major vessels were labelled as triple vessel coronary artery disease (TVCAD).

Mild hyper-homocysteinemia was defined as plasma homocysteine level of \>12--14.9 µmol/L, moderate hyper-homocysteinemia was defined as plasma homocysteine level of \>15--29.9 µmol/L, intermediate hyper-homocysteinemia was defined as plasma homocysteine level of \>30--00 µmol/L, and severe hyper-homocysteinemia was defined as plasma homocysteine level of \>100 µmol/L [@b0070].

Results {#s0020}
=======

The total number of the study population was 158 with 128 participants in the patient group and 30 participants in the control group. Case and control groups were identical in baseline characteristics and matched for each variable using the Chi-square test as shown in [Table 1](#t0005){ref-type="table"}.Table 1Basic characteristics of controls and cases.ControlCase*p*Age32.84 (±2.14)33.81 (±2.74)\<0.001 SexMales68.167.2\<0.001Females31.932.8\<0.001Smoking13.514.3\<0.001Diabetes mellitus6.47.1\<0.001Hypertension9.410.2\<0.001BMI22.95 (±2.65)23.28 (±2.08)\<0.001Homocysteine (µmol/L)6.3 (±2.05)44.5 (±14.01)0.86[^1][^2]

The control group had mean plasma homocysteine concentration 6.3 (±2.05) µmol/L whereas the patient group had mean plasma concentration of 44.5 (±14.01) µmol/L and there was a statistically positive correlation between mean homocysteine concentration of case and control groups with *p* value of 0.003 from the *t* test as shown in [Fig. 1](#f0005){ref-type="fig"}Fig. 1Comparison of plasma homocysteine concentration between cases and controls. The intensity of increase in hyper-homocystenemia, its classification as mild, moderate, intermediate, and severe, and its relationship with sex among patients is shown in [Table 2](#t0010){ref-type="table"}.

The association of hyper-homocystenemia with the number of coronary arteries involved and severity of coronary artery stenosis is depicted in [Table 3](#t0015){ref-type="table"}.Table 2Intensity of hyper-homocysteinemia and its relationship with sex.SexIntensity of Hyper-homocystenemia in patients groupTotalMild increase (12--14.9 µmol/L)Moderate increase (15--29.9 µmol/L)Intermediate increase (30--100 µmol/L)Severe increase (\>100 µmol/L)Male011 (8.6)72 (56.3)3 (2.3)86 (67.2)Female04 (3.1)37 (28.9)1 (0.8)42 (32.8)Total015 (11.7)109 (85.2)4 (3.1)128[^3]

The correlation between homocysteine level and severity of coronary artery disease (moderate or severe stenosis in 1 or more major coronary arteries) was statistically significant on Pearson's test with *r* = 0.85 and *p* \< 0.01. Homocysteine level also had statistically significant correlation with the number of major coronary arteries having moderate to severe stenosis with *r* = 0.22 and *p* \< 0.01 on Pearson's test.Table 3Association between hyper-homocysteinemia severity, number of coronary vessels involved, and severity of CAD.Severity of hyperhomocystenemiaNo. of vessels involvedSeverity of CADSVCADDVCADTVCADModerate stenosisSevere stenosisMild hyper-homocysteinemia (12--14.9 µmol/L)00000Moderate hyper-homocysteinemia (15--29.9 µmol/L)1500105Intermediate hyper-homocysteinemia (30--100 µmol/L)103510109Severe hyper-homocysteinemia (\>100 µmol/L)03104[^4]

Discussion {#s0025}
==========

A recent study conducted in the Indian population showed that plasma homocysteine levels are highter in men compared with females which is congruent to our result in which 67.2% of the patients suffering from hyper-homocysteinemia were males compared with 32.8% of females [@b0075]. Homocysteine has a prothrombotic effect by enhancing platelet aggregation via the hydrogen sulfide pathway, thus contributing to intravascular thrombosis as reported by different studies [@b0080], [@b0085]. It is hence identified and reported as an independent risk factor for atherosclerosis [@b0090], [@b0095]. Ganguly and Alam [@b0050] also identified the detrimental effect of high homocysteine levels on a cardiovascular system mediated by catecholamine and Zang et al. [@b0100] showed its deleterious effect in causing arterial stiffness. All these studies support our results which showed that all the patients with moderate to severe stenosis in one or more major coronary arteries had hyper-homocysteinemia. Amongst them, 92.2% had intermediate, 4.7% had moderate, and 3.1% had severe increase in plasma homocysteine levels. None of the patients who had moderate or severe stenosis in one or more major coronary arteries had a normal homocysteine level.

Different geographic locations and different ethnic backgrounds have different genetic responses and to evaluate hyper-homocysteinemia effect in our population we compared our results to similar studies from Asian populations. Mahalle et al. [@b0045] conducted a similar study in Asia having 216 patients with coronary artery disease, among whom 95.3% had hyper-homocysteinemia in the Indian population. Hyper-homocysteinemia was identified as a risk factor for cardiovascular thrombosis in Asian population. Mendis et al. [@b0105] conducted a case control study to look for association between the hyper-homocysteinemia and coronary artery disease in Sir Lankan patients and established a statistically significant association between the raised level of homocysteine and coronary artery disease, strengthening results of our study.

Schaffer et al. [@b0040] ran a large prospective study from March 2007 to October 2013 to look for the relationship between homocysteine and coronary artery disease including 3056 patients. They found a positive correlation between raised homocysteine levels and coronary artery disease and concluded that homocysteine was an independent risk factor for coronary artery disease.

The impact of homocysteine as an isolated and very important risk factor was hallmarked in a meta-analysis of observational studies published in *The Journal of the American Medical Association* correlating homocysteine levels with risk of ischemic heart disease, stroke, and found that low levels of homocysteine was associated with lower risk of ischemic heart disease and stroke [@b0110]. We also compared our target population age group with other studies. Raised levels of homocysteine was reported as cardiovascular risk factor in young patients in another case report, supporting our result and hypothesis [@b0115].

Yeh et al. [@b0120] showed that plasma homocysteine level was 16.4 + 6.44 µmol/L in patients with myocardial infarction. This study had limited participants and included all those patients who had primary Percutaneous Coronary Intervention (PCI) done with bare metal stent (BMS). BMS has a very limited usage and scope due to increased risk of acute stent thrombosis. Renal impairment patients were also excluded in that study which is one of the contributing factors in raising serum homocysteine concentration [@b0125]. Besides this all the patients of myocardial infarction were included regardless of their age and risk factors. These results do not truly reflect cardiovascular event as a sole result of pure hyper-homocystenemia but a cumulative role of all the risk factors in which hyper-homocystenemia contribution can be negligible in the presence of conventional strong risk factors. On the contrary, results of our study show the vascular toxic effect of pure hyper-homocystenemia in absence of conventional risk factors without synergistic and cumulative effects. High levels of plasma homocysteine are required to bring the cardiovascular toxic effects in the absence of other conventional risk factors as observed in our study. Furthermore, it was carried out in underprivileged population who are prone to develop hyper-homocystenemia [@b0130], [@b0135].

Our results showed that all the young patients with coronary artery disease had a raised homocysteine level with no young patient suffering from moderate to severe stenosis in single or multiple major coronary arteries having a normal serum homocysteine concentration. Hyper-homocystenemia is a modifiable risk factor, therefore it needs urgent attention. Targeting it will decrease both cardiovascular morbidity and mortality both in primary and secondary prevention.

Conclusion {#s0030}
==========

In absence of conventional risk factors, hyper-homocysteinemia alone can be a major risk factor for cardiovascular thrombosis and it has a positive correlation with coronary artery disease in young patients. Further studies are required to elaborate such results.

Limitations of the study {#s0035}
------------------------

Having been a case-control study, our results cannot truly depict the general population but it will provide a basis for further population based epidemiological studies and bring into the limelight the grave impact hyper-homocysteinemia is projecting as cardiovascular risk factor.

The sample size was relatively small due to low incidence of hyper-homocysteinemia in the general population and stringent inclusion--exclusion criteria.

Plasma separation time was not standardized which might have prompted technical delays in plasma separation and slightly high false levels of plasma homocysteine concentration.
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[^1]: Data are presented as% or mean (±SD).

[^2]: BMI = body mass index.

[^3]: Data are presented as *n* (%) or range.

[^4]: CAD = coronary artery disease; DVCAD = double vessel coronary artery disease; SVCAD = single vessel coronary artery disease; TVCAD = triple vessel coronary artery disease.
